Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Milena Shrashimirova, Ivan Tyanev, Wiesław J Cubała, Adam Wichniak, Claudia Vodickova-Borzova, Alessandro Ruggieri, Annalisa Bonelli, Paola Lipone, Alessandro Comandini & Agnese Cattaneo. (2023) Long-Term Treatment with Trazodone Once-A-Day (TzOAD) in Patients with MDD: An Observational, Prospective Study. Neuropsychiatric Disease and Treatment 19, pages 1181-1193.
Read now
Read now
Cedo D. Miljevic, Dusica Lečić-Toševski & Trazodone Study Group Serbia. (2016) Efficacy and tolerability of trazodone retard monotherapy: results of the Serbian non-interventional study. International Journal of Psychiatry in Clinical Practice 20:3, pages 133-140.
Read now
Read now
Arianna Goracci, Rocco N Forgione, Riccardo De Giorgi, Anna Coluccia, Alessandro Cuomo & Andrea Fagiolini. (2016) Practical guidance for prescribing trazodone extended-release in major depression. Expert Opinion on Pharmacotherapy 17:3, pages 433-441.
Read now
Read now
Rita Moretti, Elena Bernobich, Francesca Esposito, Paola Torre, Rodolfo M Antonello, Luisa De Angelis & Giuseppe Bellini. (2011) Depression in vascular pathologies: the neurologist’s point of view. Vascular Health and Risk Management 7, pages 433-443.
Read now
Read now
Marian W. Roman. (2011) New Additions to the Psychopharmacopia: Extended Release Formulations. Issues in Mental Health Nursing 32:11, pages 717-719.
Read now
Read now
Richard E. Kast. (2009) Trazodone generates m-CPP: In 2008 risks from m-CPP might outweigh benefits of trazodone. The World Journal of Biological Psychiatry 10:4-2, pages 682-685.
Read now
Read now
Articles from other publishers (29)
Dominika Dudek, Adrian Andrzej Chrobak, Anna Julia Krupa, Aleksandra Gorostowicz, Adrian Gerlich, Andrzej Juryk & Marcin Siwek. (2023) TED—trazodone effectiveness in depression: a naturalistic study of the effeciveness of trazodone in extended release formulation compared to SSRIs in patients with a major depressive disorder. Frontiers in Pharmacology 14.
Crossref
Crossref
Andrea Fagiolini, Ana González-Pinto, Kamilla Woznica Miskowiak, Pedro Morgado, Allan H. Young & Eduard Vieta. (2023) Role of trazodone in treatment of major depressive disorder: an update. Annals of General Psychiatry 22:1.
Crossref
Crossref
John J. Maurer, Ashley Choi, Isabella An, Nicholas Sathi & Shinjae Chung. (2023) Sleep disturbances in autism spectrum disorder: Animal models, neural mechanisms, and therapeutics. Neurobiology of Sleep and Circadian Rhythms 14, pages 100095.
Crossref
Crossref
Jan Čermák, Slavomír Pietrucha, Alexander Nawka, Paola Lipone, Alessandro Ruggieri, Annalisa Bonelli, Alessandro Comandini & Agnese Cattaneo. (2023) An Observational Pilot Study using a Digital Phenotyping Approach in Patients with Major Depressive Disorder Treated with Trazodone. Frontiers in Psychiatry 14.
Crossref
Crossref
Marcin Siwek, Aleksandra Gorostowicz, Adrian Andrzej Chrobak, Adrian Gerlich, Anna Julia Krupa, Andrzej Juryk & Dominika Dudek. (2023) TED—Trazodone Efficacy in Depression: A Naturalistic Study on the Efficacy of Trazodone in an Extended-Release Formulation Compared to SSRIs in Patients with a Depressive Episode—Preliminary Report. Brain Sciences 13:1, pages 86.
Crossref
Crossref
D.V. Romanov, M.D. Samsonova & P.G. Iuzbashian. (2023) Treatment of mental disorders caused or triggered by somatic and neurological diseases with the use of the multimodal antidepressant trazodone. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 123:4, pages 81.
Crossref
Crossref
Joseph F. Goldberg, Michael Q. Steinman & Stephen M. Stahl. (2023) Trazodone once-a-day: A formula for addressing challenges in antidepressant safety and tolerability. Neuroscience Applied 2, pages 101127.
Crossref
Crossref
Umberto Albert, Pallavi Lamba & Stephen M. Stahl. (2021) Early response to trazodone once-a-day in major depressive disorder: review of the clinical data and putative mechanism for faster onset of action. CNS Spectrums 26:3, pages 232-242.
Crossref
Crossref
Christian P. Cheung, Mathura T. Thiyagarajah, Haben Y. Abraha, Celina S. Liu, Krista L. Lanctôt, Alex J. Kiss, Mahwesh Saleem, Ari Juda, Anthony J. Levitt, Ayal Schaffer, Amy H. Cheung & Mark Sinyor. (2021) The association between placebo arm inclusion and adverse event rates in antidepressant randomized controlled trials: An examination of the Nocebo Effect. Journal of Affective Disorders 280, pages 140-147.
Crossref
Crossref
Valeria Tellone, Maria Teresa Rosignoli, Rossella Picollo, Patrizia Dragone, Alessandra Del Vecchio, Alessandro Comandini, Milko Radicioni, Chiara Leuratti & Fabrizio Calisti. (2020) Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects. The Journal of Clinical Pharmacology 60:11, pages 1483-1495.
Crossref
Crossref
Sunyoung Park, Won-Jung Choi, Sejoo Kim, Borah Kim, Sang Joon Son, Daeyoung Roh, Woo Jung Kim & Jin Young Park. (2020) Effects of transcranial direct current stimulation using miniaturized devices vs sertraline for depression in Korea: A 6 week, multicenter, randomized, double blind, active-controlled study. Journal of Psychiatric Research 127, pages 42-47.
Crossref
Crossref
Lorenzo Guizzaro, David Dickinson Vaughan Morgan, Andrea Falco & Ciro Gallo. (2020) Hamilton scale and MADRS are interchangeable in meta-analyses but can disagree at trial level. Journal of Clinical Epidemiology 124, pages 106-117.
Crossref
Crossref
Andrea Fagiolini, Umberto Albert, Laura Ferrando, Erik Herman, Cosmina Muntean, Eva Pálová, Agnese Cattaneo, Alessandro Comandini, Giorgio Di Dato, Giorgio Di Loreto, Luisa Olivieri, Enrica Salvatori, Serena Tongiani & Siegfried Kasper. (2020) A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder. International Clinical Psychopharmacology 35:3, pages 137-146.
Crossref
Crossref
Daniel J. Buysse & Shachi Tyagi. 2017. Principles and Practice of Sleep Medicine. Principles and Practice of Sleep Medicine
432
445.e7
.
Ai Leng Khoo, Hui Jun Zhou, Monica Teng, Liang Lin, Ying Jiao Zhao, Lay Beng Soh, Yee Ming Mok, Boon Peng Lim & Kok Peng Gwee. (2015) Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants. CNS Drugs 29:8, pages 695-712.
Crossref
Crossref
Katherine A. Lyseng-Williamson. (2015) Trazodone prolonged release: a guide to its use in depression. Drugs & Therapy Perspectives 31:5, pages 137-142.
Crossref
Crossref
Barbara Nussbaumer, Laura C. Morgan, Ursula Reichenpfader, Amy Greenblatt, Richard A. Hansen, Megan Van Noord, Linda Lux, Bradley N. Gaynes & Gerald Gartlehner. (2014) Comparative Efficacy and Risk of Harms of Immediate- versus Extended-Release Second-Generation Antidepressants: A Systematic Review with Network Meta-Analysis. CNS Drugs 28:8, pages 699-712.
Crossref
Crossref
Lin Zhang, Wei-Wei Xie, Le-Hua Li, Hong-Geng Zhang, Gang Wang, Da-Chun Chen, Yi Cao, Li-Jun Cui, Ke-Rang Zhang, Jian-Guo Shi, Qing-Rong Tan, Hong-Bo Zheng, Xiu-Feng Xu, Zao-Huo Cheng & Jing-Ping Zhao. (2014) Efficacy and Safety of Prolonged-Release Trazodone in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Flexible-Dose Trial. Pharmacology 94:5-6, pages 199-206.
Crossref
Crossref
Andrea Fagiolini, Alessandro Comandini, Mario Catena Dell’Osso & Siegfried Kasper. (2012) Rediscovering Trazodone for the Treatment of Major Depressive Disorder. CNS Drugs 26:12, pages 1033-1049.
Crossref
Crossref
Dan J SteinMichael Van AmeringenBeth PattersonElizabeth Lee. 2012. Antidepressants and Major Depressive Disorder. Antidepressants and Major Depressive Disorder
26
47
.
Benjamin Raatjes & Bezalel Dantz. (2011) Trazodone: The Forgotten Antidepressant. Psychiatric Annals 41:3, pages 148-157.
Crossref
Crossref
Daniel J. Buysse. 2011. Principles and Practice of Sleep Medicine. Principles and Practice of Sleep Medicine
492
509
.
Andrea Cipriani, Teresa La Ferla, Toshi A Furukawa, Alessandra Signoretti, Atsuo Nakagawa, Rachel Churchill, Hugh McGuire & Corrado Barbui. (2010) Sertraline versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Andrea Cipriani, Teresa La Ferla, Toshi A Furukawa, Alessandra Signoretti, Atsuo Nakagawa, Rachel Churchill, Hugh McGuire & Corrado Barbui. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
George I. Papakostas & Maurizio Fava. (2020) Metanálisis de ensayos clínicos que compararon los antagonistas de los receptores de serotonina (5HT)-2 trazodona y nefazodona con inhibidores selectivos de la recaptación de serotonina para el tratamiento del trastorno depresivo mayor. European psychiatry (Ed. Española) 15:1, pages 18-22.
Crossref
Crossref
Gerald Gartlehner, Patricia Thieda, Richard A Hansen, Bradley N Gaynes, Angela DeVeaugh-Geiss, Erin E Krebs & Kathleen N Lohr. (2008) Comparative Risk for Harms of Second-Generation Antidepressants. Drug Safety 31:10, pages 851-865.
Crossref
Crossref
George I. Papakostas & Maurizio Fava. (2007) A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. European Psychiatry 22:7, pages 444-447.
Crossref
Crossref
Lola Roldán-Tapia, Rosa Cánovas-López, José Cimadevilla & Matías Valverde. (2007) Déficit mnésicos y perceptivos en la fibromialgia y la artritis reumatoide. Reumatología Clínica 3:3, pages 101-109.
Crossref
Crossref
Lola Roldán-Tapia, Rosa Cánovas-López, José Cimadevilla & Matías Valverde. (2007) Cognition and Perception Deficits in Fibromyalgia and Rheumatoid Arthritis. Reumatología Clínica (English Edition) 3:3, pages 101-109.
Crossref
Crossref